- Email: [email protected]
4504413 Acetaminophen analogs, antigens, and antibodies
128
PATENT ABSTRACTS
preparative scale to provide homogeneous end product in excellent yield. In an embodiment of the process, human interferon is produced as a homogeneous protein.
4503039 COAGULANT PLASMA-PROTEIN SOLUTION Ronald Kotitschke, Wolfgang Stephan, Dreieich, Federal Republic Of Germany assigned to Biotest-Serum-lnstitut GmbH
4503036 PROCESS FOR PRODUCING BIOCHEMICAL VACCINE AGAINST SALMONELLA INFECTION
A
Philippe Girardon, Jean Amen, Versailles, France assigned to L'Air Liquide Societe Anonyme Pour l'Etude et l'Exploitation des Procedes Georges Claude A bacterial vaccine against Salmonella levers, typhoid and paratyphoid fevers is obtained by fermentation, extraction and purification, vaccinating membrane antigens being extracted by putting the bacterial residue, obtained by centrifuging, in contact with a solvent of the tris (hydroxyalkyl) aminoalkane class, with stirring, at lowered temperature, pH adjusted between 8.4 and 8.6 for a period of at least some 60 hours, then, separated by decanting, followed by purifying the antigens and fractionating by ultrafiltration, and then freeze-drying the vaccinating antigen fraction. Such vaccinating antigen fraction has a molecular weight greater than 50,000, preferably 300,000, and is used to vaccinate humans and animals.
A coagulant plasma-protein solution obtained by adsorbing stabilized human plasma at least once with 20-40 mg of colloidal silicic acid per gram of plasma protein and separating the adsorbent from the adsorbate, a method of manufacturing the solution, and a pharmaceutical preparation containing the solution and intended for the intravenous treatment of complex disorders of the hemostatic system. The solution is low in fibrinogen and factors X1 and XII but otherwise close in composition to the starting material.
4503155 MULTIFUNCTIONAL, CLONING VECTORS FOR USE IN STREPTOMYCES, BACILLUS, A N D E. C O L I James Miller, Jeffrey T Fayerman, Steven Kovacevic, Nancy E Beerman assigned to Eli Lilly and Company ~
lind Fun~'~onal Map
of Plssmld pLR2
4503038 EXTRACELLULAR NONMITOGENIC ANGIOGENESIS FACTOR AND METHOD OF ISOLATION THEREOF FROM WOUND FLUID Michael J Banda, Zena Werb, David R Knighton, Thomas K Hunt assigned to The Regents of the University of California A nonmitogenic angiogenesis factor is isolated from wound fluid by dialysis to include materials in the molecular size range of 2,000 to 14, 000, lyophilization, and chromatography. The nonmitogenic angiogenesis factor is identified by activity by corneal implant assay and by cell migration assay. The angiogenesis factor is also characterized by inactivity by mitogenesis assay.
~mm
The present invention discloses multifunctional recombinant DNA cloning vectors for use in Streptomyces, Bacillus, and E. coll. The invention further discloses transformants of the aforementioned vectors.
4504413 ACETAMINOPHEN ANALOGS, ANTIGENS, AND ANTIBODIES Pyar Khanna assigned to Syva Company
PATENT ABSTRACTS Y
129
4504584
Z
CULTURES OF NOVEL STRAINS OF STREPTOMYCES Carbonyl derivatives ofacetaminophen are provided for use in homogeneous enzyme immunoassays for acetaminophen. The derivatives are conjugated to antigenic substances for the preparation of antisera specific to acetaminophen, and to enzymes for the preparation of enzyme conjugates which compete with acetaminophen for antibody binding sites in a typical assay.
Yoshihiko Kitaura, Osamu Nakaguchi, Keiji Hemmi, Matsuhiko Aratani, Hidekazu Takeno, Satoshi Okada, Hirokazu Tanaka, Masashi Hashimoto, Yoshio Kuroda, Eiko lguchi, Masanobu Kohsaka, Hatsuo Aoki, Hiroshi Imanaka, Sakurai, Japan assigned to Fujisawa Pharmaceutical Co Ltd
4504471 ANIMAL GROWTH PROMOTANT AND METHOD OF USE FOR ANIMAL GROWTH Hirofumi Takagi, Kiyohiko Kunugita, Hideki Sawai, Kazuo Kariyone, Sakura, Japan assigned to Fujisawa Pharmaceutical Co Ltd
~H ~H3 (D) CH3CHCONHCHCONHCHCOOH (D)
RI--HNCHCOOH
t
(CH2)2 t
COHNCHCO--R 2
(L)
CH2 I
CH2 ] (L) CONHCHCONHCH2COOH I
(CH2 i3
H2NCH--R 3
This invention relates to a new animal growth promotant which comprises an awl peptide or its non-toxic salt as an active ingredient. In addition, this invention also relates to a method for promoting the growth of animals, to a method of improving the rate of weight gain of animals, and to a method of improving the efficiency of feed utilization by animals which comprises administering orally the animal growth promotant and a suitable carrier or animal feed to animals.
4504582 VERMICULITE AS A CARRIER SUPPORT FOR IMMOBILIZED BIOLOGICAL MATERIALS Wayne E Swann assigned to Genex Corporation Biological materials are immobilized by being absorbed into vermiculite particles which then are coated with a polymeric coating material. A variety of cross-linking, condensing, and gelling agents may be used to strengthen and crosslink the polymer.
CH2
I
H2NCHCOOH (D)
The invention relates to a biologically pure culture of new strains of the microorganism Streptomyces which are capable upon fermentation of producing a peptide of pharmacological activity.
4504586 HYBRIDOMA TUMOR CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN COLONY STIMULATING FACTOR SUBCLASS NUMBER 1 Marger Nicolson assigned to Amgen Murine-derived hybridoma tumor cell lines and monoclonal anti-Colony Stimulating Factor Subclass Number 1 antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of natural Colony Stimulating Factor Subclass Number I and for quantitative detection of colony Stimulating Factor Subclass Number l in fluid samples.
PATENT ABSTRACTS
preparative scale to provide homogeneous end product in excellent yield. In an embodiment of the process, human interferon is produced as a homogeneous protein.
4503039 COAGULANT PLASMA-PROTEIN SOLUTION Ronald Kotitschke, Wolfgang Stephan, Dreieich, Federal Republic Of Germany assigned to Biotest-Serum-lnstitut GmbH
4503036 PROCESS FOR PRODUCING BIOCHEMICAL VACCINE AGAINST SALMONELLA INFECTION
A
Philippe Girardon, Jean Amen, Versailles, France assigned to L'Air Liquide Societe Anonyme Pour l'Etude et l'Exploitation des Procedes Georges Claude A bacterial vaccine against Salmonella levers, typhoid and paratyphoid fevers is obtained by fermentation, extraction and purification, vaccinating membrane antigens being extracted by putting the bacterial residue, obtained by centrifuging, in contact with a solvent of the tris (hydroxyalkyl) aminoalkane class, with stirring, at lowered temperature, pH adjusted between 8.4 and 8.6 for a period of at least some 60 hours, then, separated by decanting, followed by purifying the antigens and fractionating by ultrafiltration, and then freeze-drying the vaccinating antigen fraction. Such vaccinating antigen fraction has a molecular weight greater than 50,000, preferably 300,000, and is used to vaccinate humans and animals.
A coagulant plasma-protein solution obtained by adsorbing stabilized human plasma at least once with 20-40 mg of colloidal silicic acid per gram of plasma protein and separating the adsorbent from the adsorbate, a method of manufacturing the solution, and a pharmaceutical preparation containing the solution and intended for the intravenous treatment of complex disorders of the hemostatic system. The solution is low in fibrinogen and factors X1 and XII but otherwise close in composition to the starting material.
4503155 MULTIFUNCTIONAL, CLONING VECTORS FOR USE IN STREPTOMYCES, BACILLUS, A N D E. C O L I James Miller, Jeffrey T Fayerman, Steven Kovacevic, Nancy E Beerman assigned to Eli Lilly and Company ~
lind Fun~'~onal Map
of Plssmld pLR2
4503038 EXTRACELLULAR NONMITOGENIC ANGIOGENESIS FACTOR AND METHOD OF ISOLATION THEREOF FROM WOUND FLUID Michael J Banda, Zena Werb, David R Knighton, Thomas K Hunt assigned to The Regents of the University of California A nonmitogenic angiogenesis factor is isolated from wound fluid by dialysis to include materials in the molecular size range of 2,000 to 14, 000, lyophilization, and chromatography. The nonmitogenic angiogenesis factor is identified by activity by corneal implant assay and by cell migration assay. The angiogenesis factor is also characterized by inactivity by mitogenesis assay.
~mm
The present invention discloses multifunctional recombinant DNA cloning vectors for use in Streptomyces, Bacillus, and E. coll. The invention further discloses transformants of the aforementioned vectors.
4504413 ACETAMINOPHEN ANALOGS, ANTIGENS, AND ANTIBODIES Pyar Khanna assigned to Syva Company
PATENT ABSTRACTS Y
129
4504584
Z
CULTURES OF NOVEL STRAINS OF STREPTOMYCES Carbonyl derivatives ofacetaminophen are provided for use in homogeneous enzyme immunoassays for acetaminophen. The derivatives are conjugated to antigenic substances for the preparation of antisera specific to acetaminophen, and to enzymes for the preparation of enzyme conjugates which compete with acetaminophen for antibody binding sites in a typical assay.
Yoshihiko Kitaura, Osamu Nakaguchi, Keiji Hemmi, Matsuhiko Aratani, Hidekazu Takeno, Satoshi Okada, Hirokazu Tanaka, Masashi Hashimoto, Yoshio Kuroda, Eiko lguchi, Masanobu Kohsaka, Hatsuo Aoki, Hiroshi Imanaka, Sakurai, Japan assigned to Fujisawa Pharmaceutical Co Ltd
4504471 ANIMAL GROWTH PROMOTANT AND METHOD OF USE FOR ANIMAL GROWTH Hirofumi Takagi, Kiyohiko Kunugita, Hideki Sawai, Kazuo Kariyone, Sakura, Japan assigned to Fujisawa Pharmaceutical Co Ltd
~H ~H3 (D) CH3CHCONHCHCONHCHCOOH (D)
RI--HNCHCOOH
t
(CH2)2 t
COHNCHCO--R 2
(L)
CH2 I
CH2 ] (L) CONHCHCONHCH2COOH I
(CH2 i3
H2NCH--R 3
This invention relates to a new animal growth promotant which comprises an awl peptide or its non-toxic salt as an active ingredient. In addition, this invention also relates to a method for promoting the growth of animals, to a method of improving the rate of weight gain of animals, and to a method of improving the efficiency of feed utilization by animals which comprises administering orally the animal growth promotant and a suitable carrier or animal feed to animals.
4504582 VERMICULITE AS A CARRIER SUPPORT FOR IMMOBILIZED BIOLOGICAL MATERIALS Wayne E Swann assigned to Genex Corporation Biological materials are immobilized by being absorbed into vermiculite particles which then are coated with a polymeric coating material. A variety of cross-linking, condensing, and gelling agents may be used to strengthen and crosslink the polymer.
CH2
I
H2NCHCOOH (D)
The invention relates to a biologically pure culture of new strains of the microorganism Streptomyces which are capable upon fermentation of producing a peptide of pharmacological activity.
4504586 HYBRIDOMA TUMOR CELL LINES AND THEIR MONOCLONAL ANTIBODIES TO HUMAN COLONY STIMULATING FACTOR SUBCLASS NUMBER 1 Marger Nicolson assigned to Amgen Murine-derived hybridoma tumor cell lines and monoclonal anti-Colony Stimulating Factor Subclass Number 1 antibody substances produced by these cell lines. Use of said monoclonal antibody substances, alone or in combination, in immunological procedures for isolation of natural Colony Stimulating Factor Subclass Number I and for quantitative detection of colony Stimulating Factor Subclass Number l in fluid samples.